B cell receptor associated protein 31Genealiases: 6C6-AG · BAP31 · CDM · DDCH · DELXQ28 · DXS1357E
Q-omics provides the consensus-scored BCAP31 profile across patient tissues and cancer cell-line models. BCAP31 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BCAP31 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, BCAP31 RNA expression shows 17,969 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, and ACC as cancer lineages where BCAP31 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BCAP31 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BCAP31 survival associations across molecular data types. BCAP31 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BCAP31 RNA expression–survival associations across cancer types. High BCAP31 expression shows unfavorable associations in HNSC, ESCA, KIRP, KICH, LGG and BRCA. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BCAP31 RNA expression.
This table summarizes BCAP31 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for BCAP31. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BCAP31 shows higher tumor expression in HNSC, KIRC, COAD, LIHC, KIRP and BLCA. The HNSC box plot shows higher BCAP31 RNA expression in tumor versus normal tissue (log2 FC = +1.029, t-test p < 0.001).
This table shows molecular features associated with BCAP31 in patient tissues and cancer cell lines. In patient samples, BCAP31 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, BCAP31 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and UPPER_AERODIGESTIVE_TRACT.
